Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2019 | 93 | 1.35 | Why? |
| Fecal Microbiota Transplantation | 2 | 2019 | 372 | 1.01 | Why? |
| Hidradenitis Suppurativa | 3 | 2019 | 309 | 0.38 | Why? |
| Adrenal Cortex Hormones | 3 | 2021 | 6537 | 0.38 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.30 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.29 | Why? |
| Renal Insufficiency, Chronic | 1 | 2019 | 2654 | 0.27 | Why? |
| Hydroxychloroquine | 4 | 2020 | 12447 | 0.25 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.24 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.24 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.24 | Why? |
| Organ Transplantation | 3 | 2021 | 2616 | 0.22 | Why? |
| Anti-Bacterial Agents | 3 | 2019 | 10083 | 0.21 | Why? |
| Inflammatory Bowel Diseases | 1 | 2017 | 3209 | 0.20 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.19 | Why? |
| Metronidazole | 1 | 2019 | 59 | 0.19 | Why? |
| Hypertriglyceridemia | 1 | 2020 | 90 | 0.19 | Why? |
| Cytosine Deaminase | 1 | 2018 | 14 | 0.19 | Why? |
| Mycobacterium marinum | 1 | 2017 | 4 | 0.18 | Why? |
| Paracentesis | 1 | 2017 | 25 | 0.18 | Why? |
| Tumor Virus Infections | 1 | 2018 | 127 | 0.17 | Why? |
| BK Virus | 1 | 2018 | 135 | 0.16 | Why? |
| Polyomavirus Infections | 1 | 2018 | 156 | 0.16 | Why? |
| Dermatologic Surgical Procedures | 1 | 2019 | 138 | 0.16 | Why? |
| Streptococcus pyogenes | 1 | 2017 | 118 | 0.16 | Why? |
| Hand Injuries | 1 | 2017 | 110 | 0.15 | Why? |
| Transplant Recipients | 3 | 2021 | 4982 | 0.15 | Why? |
| Vancomycin | 1 | 2019 | 328 | 0.15 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2017 | 167 | 0.14 | Why? |
| Doxycycline | 1 | 2017 | 307 | 0.14 | Why? |
| Macrolides | 1 | 2017 | 369 | 0.13 | Why? |
| Secondary Prevention | 1 | 2019 | 762 | 0.13 | Why? |
| Streptococcal Infections | 1 | 2017 | 255 | 0.13 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.13 | Why? |
| Patients | 1 | 2021 | 1167 | 0.13 | Why? |
| Clostridium Infections | 1 | 2019 | 595 | 0.11 | Why? |
| Recurrence | 2 | 2018 | 3675 | 0.10 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Health Care Costs | 1 | 2019 | 1007 | 0.10 | Why? |
| Antimicrobial Stewardship | 1 | 2019 | 931 | 0.10 | Why? |
| Immunocompromised Host | 2 | 2017 | 5150 | 0.10 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.10 | Why? |
| Graft Rejection | 1 | 2020 | 1766 | 0.10 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.09 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.09 | Why? |
| Hand Hygiene | 1 | 2019 | 1493 | 0.09 | Why? |
| Inpatients | 2 | 2020 | 5161 | 0.09 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.09 | Why? |
| Health Resources | 1 | 2020 | 2592 | 0.08 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Anti-Infective Agents | 1 | 2019 | 1766 | 0.08 | Why? |
| Michigan | 2 | 2020 | 988 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Communicable Diseases | 1 | 2021 | 2148 | 0.08 | Why? |
| Skin | 1 | 2017 | 2096 | 0.07 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.07 | Why? |
| Patient Isolation | 1 | 2019 | 3182 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.06 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2019 | 3222 | 0.06 | Why? |
| Humans | 21 | 2021 | 930598 | 0.06 | Why? |
| Retrospective Studies | 8 | 2020 | 105322 | 0.06 | Why? |
| Male | 13 | 2021 | 367725 | 0.05 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
| Female | 12 | 2020 | 380317 | 0.05 | Why? |
| Hospital Mortality | 2 | 2020 | 22087 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| APOBEC Deaminases | 1 | 2018 | 58 | 0.04 | Why? |
| Chromosome Mapping | 1 | 2018 | 178 | 0.04 | Why? |
| Retreatment | 1 | 2018 | 186 | 0.04 | Why? |
| Cytidine Deaminase | 1 | 2018 | 109 | 0.04 | Why? |
| Kidney Transplantation | 1 | 2018 | 5397 | 0.04 | Why? |
| Skin Diseases, Bacterial | 1 | 2017 | 105 | 0.04 | Why? |
| Fasciitis, Necrotizing | 1 | 2017 | 56 | 0.04 | Why? |
| Aged | 8 | 2020 | 215776 | 0.04 | Why? |
| Infusions, Intravenous | 1 | 2020 | 1224 | 0.04 | Why? |
| DNA Damage | 1 | 2018 | 285 | 0.04 | Why? |
| Soft Tissue Infections | 1 | 2017 | 116 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Capsid Proteins | 1 | 2018 | 365 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Adult | 8 | 2020 | 244371 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2020 | 1475 | 0.03 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2018 | 1706 | 0.03 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.03 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.03 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.02 | Why? |
| Infection Control | 1 | 2019 | 23131 | 0.02 | Why? |
| Congresses as Topic | 1 | 2018 | 1347 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2019 | 2483 | 0.02 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.02 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.02 | Why? |
| Shock, Septic | 1 | 2017 | 1313 | 0.02 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.02 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.02 | Why? |
| New York City | 1 | 2020 | 7432 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.02 | Why? |
| African Americans | 1 | 2020 | 3363 | 0.02 | Why? |
| Referral and Consultation | 1 | 2021 | 4816 | 0.02 | Why? |
| HEK293 Cells | 1 | 2018 | 8394 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| United States | 2 | 2020 | 46150 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.02 | Why? |
| Ultrasonography | 1 | 2019 | 4409 | 0.01 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2019 | 6153 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Biomedical Research | 1 | 2019 | 5270 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Italy | 1 | 2018 | 38444 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2018 | 25288 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2017 | 88759 | 0.00 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.00 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |
| Antibodies, Viral | 1 | 2018 | 51949 | 0.00 | Why? |